Amyloid beta 42 aggregate (Aβ42 aggregate)

Amyloid beta 42 aggregate refers to pathological assemblies of the 42-amino acid peptide derived from amyloid precursor protein (APP) cleavage, specifically the Aβ1–42 isoform. These aggregates include a spectrum of misfolded species such as soluble oligomers, protofibrils, and mature fibrils, all of which are found in the brains of Alzheimer's disease patients. Aβ42 aggregates more readily than Aβ40 due to its more hydrophobic C-terminus and forms the core of amyloid plaques characteristic of Alzheimer’s pathology[1][3][4][6][8]. Oligomeric Aβ42 species are considered the most neurotoxic, impairing synaptic function, inducing neuronal death, and contributing to cognitive decline[2][4][6]. Larger aggregated forms such as fibrils are also neurotoxic and are the prominent species in amyloid plaques[1][3][7]. The presence and species of Aβ42 aggregates serve as key biomarkers for Alzheimer's diagnosis and progression, and several disease-modifying therapies have been developed to target these aggregates through antibody-mediated neutralization or stimulation of aggregate clearance[4][6]. Safety concerns primarily relate to immune reactions or cerebral edema in response to anti-Aβ therapies.

Other names

Amyloid-β(1–42) aggregateAβ42 fibrilAβ42 oligomerbeta-amyloid 42 aggregateamyloid beta-protein 42 aggregateAlzheimer's beta-amyloid 42 aggregate

Antibody-mediated clearance (immunotherapy targeting aggregated Aβ42); Inhibition of oligomerization or fibril formation; Disruption of Aβ aggregation; Promotion of aggregate clearance via microglia or phagocytosis